Literature DB >> 21926615

Survival in neutropenic patients with severe sepsis or septic shock.

Matthieu Legrand1, Adeline Max, Vincent Peigne, Eric Mariotte, Emmanuel Canet, Alexandre Debrumetz, Virginie Lemiale, Amélie Seguin, Michael Darmon, Benoît Schlemmer, Elie Azoulay.   

Abstract

OBJECTIVE: To determine whether the survival gains achieved in critically ill cancer patients in recent years exist in the subset with neutropenia and severe sepsis or septic shock.
DESIGN: Retrospective 11-yr study (1998-2008).
SETTING: Medical intensive care unit in a teaching hospital. PATIENTS: Four hundred twenty-eight intensive care unit patients with cancer, neutropenia, and severe sepsis or septic shock. The primary outcome was hospital mortality.
RESULTS: The main underlying diseases were acute leukemia (35.7%), lymphoma (31.7%), and solid tumors (16.5%). Two hundred thirty-seven (55.5%) patients had microbiologically documented infections, 141 (32.9%) clinically documented infections, and 50 (11.9%) fever of unknown origin. Acute noninfectious conditions were diagnosed in 175 of 428 (41%) patients, including 26 of 50 (52%) patients with fever of unknown origin, 66 of 141 (47%) patients with clinically documented infections, and 83 of 237 (35%) patients with microbiologically documented infections. Early indwelling catheter removal was performed routinely in the 107 (25%) patients without clinical evidence of a septic focus at intensive care unit admission. Early beta-lactam plus aminoglycoside therapy was used in 391 (91.3%) patients. Hospital mortality was 49.8%. Hospital mortality decreased from 58.7% (108 of 184) in 1998-2003 to 43% in 2004-2008 (105 of 244, p = .006). Multivariate analysis identified nine independent predictors of hospital mortality, of which six were associated with higher mortality (older age; need for vasopressors; neurologic, respiratory, or hepatic dysfunction; and acute noninfectious condition) and three with lower mortality (intensive care unit admission after 2003, combination antibiotic therapy including an aminoglycoside, and early indwelling catheter removal).
CONCLUSION: In neutropenic patients with severe sepsis or septic shock, survival improved over time. Aminoglycoside use and early catheter removal in patients with undocumented sepsis may improve survival. Acute noninfectious conditions are associated with increased mortality, underlining the need for thorough and repeated clinical assessments.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21926615     DOI: 10.1097/CCM.0b013e31822b50c2

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  84 in total

Review 1.  Febrile neutropenia in hematologic malignancies.

Authors:  Michael K Keng; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

2.  Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia.

Authors:  Lisa M Daniels; Urshila Durani; Jason N Barreto; John C O'Horo; Mustaqeem A Siddiqui; John G Park; Pritish K Tosh
Journal:  Support Care Cancer       Date:  2019-02-25       Impact factor: 3.603

3.  Sepsis in the severely immunocompromised patient.

Authors:  Andre C Kalil; Steven M Opal
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

4.  Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia.

Authors:  Regis G Rosa; Luciano Z Goldani
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

Review 5.  [Hematological-oncological intensive care patients : Treatment without borders].

Authors:  M Kochanek; A Shimabukuro-Vornhagen; B Böll
Journal:  Med Klin Intensivmed Notfmed       Date:  2019-02-06       Impact factor: 0.840

6.  [Mortality of hematology-oncology patients with neutropenia in intensivecare].

Authors:  I Suárez; B Böll; A Shimabukuro-Vornhagen; G Michels; M von Bergwelt-Baildon; M Kochanek
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-05-21       Impact factor: 0.840

Review 7.  The Intensive Care Medicine research agenda on critically ill oncology and hematology patients.

Authors:  Elie Azoulay; Peter Schellongowski; Michael Darmon; Philippe R Bauer; Dominique Benoit; Pieter Depuydt; Jigeeshu V Divatia; Virginie Lemiale; Maarten van Vliet; Anne-Pascale Meert; Djamel Mokart; Stephen M Pastores; Anders Perner; Frédéric Pène; Peter Pickkers; Kathryn A Puxty; Francois Vincent; Jorge Salluh; Ayman O Soubani; Massimo Antonelli; Thomas Staudinger; Michael von Bergwelt-Baildon; Marcio Soares
Journal:  Intensive Care Med       Date:  2017-07-19       Impact factor: 17.440

8.  Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy-induced febrile neutropenia.

Authors:  Youn-Jung Kim; Sung Min Jung; Jihoon Kang; Seung Mok Ryoo; Chang Hwan Sohn; Dong-Woo Seo; Kyoung Soo Lim; Jin Won Huh; Sung-Han Kim; Won Young Kim
Journal:  Intern Emerg Med       Date:  2019-01-01       Impact factor: 3.397

9.  Management of Acute Respiratory Failure in Patients With Hematological Malignancy.

Authors:  Rakesh Vadde; Stephen M Pastores
Journal:  J Intensive Care Med       Date:  2016-07-07       Impact factor: 3.510

Review 10.  [Chronic critically ill patients from the perspective of hematologists/oncologists].

Authors:  T Staudinger; P Schellongowski
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-02-28       Impact factor: 0.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.